azd9291 for acquired resistance in egfr positive lung cancer
Published 10 years ago • 706 plays • Length 11:36Download video MP4
Download video MP3
Similar videos
-
4:10
3rd generation drug for acquired resistance in egfr lung cancer
-
2:26
patterns of acquired resistance to egfr tkis in egfr mutation-positive nsclc
-
4:26
combinations and other options for acquired resistance in egfr mutation-positive nsclc
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
26:27
novel egfr inhibitors in the setting of acquired resistance
-
3:07
third generation egfr tkis for acquired resistance
-
4:22
what is egfr in lung cancer? - 2022 program: targeted therapies forum
-
9:28
asco 2021 lung: amivantamab lazertinib in egfr, patritumab deruxtecan in egfr acquired resistance
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
10:16
overcoming resistance in egfr nsclc - lung cancer onctalk 2022
-
3:02
resistance mechanisms in egfr nsclc treatment - targeted therapies in lung cancer 2023
-
18:44
2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
13:53
emerging options for t790m-positive acquired resistance
-
6:26
metastatic egfr nsclc: recent developments - targeted therapies in lung cancer 2023
-
5:51
how do we approach acquired resistance to targeted therapies in lung cancer?
-
1:17:52
egfr initial treatment, acquired resistance and q&a with h. jack west, md and helena yu, md
-
24:36
treatment options for egfr t790m negative acquired resistance